Apr 06, 2020
OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact® in Patients With Primary Hyperoxaluria
Mar 12, 2020
Oxabact® Treatment Combined With Intensive Dialysis Lowers Plasma Oxalate and Halts Disease Progression in a Patient With Severe Infantile Oxalosis
Nov 07, 2019
OxThera Presents Full 24-month Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients With ESRD at Kidney Week 2019
Aug 23, 2019
OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes
Jun 27, 2019
Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria
Jun 20, 2019
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
Nov 15, 2018
OxThera AB is Being Granted US Patent for Oxalobacter Secretagogues
Oct 31, 2018
OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD
Sep 07, 2018
Hugo Petit Appointed CFO of OxThera
Jul 10, 2018
OxThera Updates on Phase 3 Study With Oxabact® in Primary Hyperoxaluria
Jun 12, 2018
OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors
Mar 14, 2018
OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact
Nov 08, 2017
OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria
Oct 13, 2017
Dr. Bastian Dehmel Appointed CMO of OxThera
Jul 05, 2017
Matthew Gantz Appointed CEO of OxThera